-
Diagnostics World News | A blood test detects T cells activated by Borrelia burgdorferi, the bacterium that causes Lyme disease; a new artificial intelligence model accurately identifies patients at increased risk of undiagnosed structural heart disease; newborn screening for sickle cell disease expands in sub-Saharan Africa; a new melanoma test accurately assesses and classifies advanced melanoma patients as likely or unlikely to benefit from immune checkpoint inhibitor therapies; and more.
Jun 30, 2022
-
Diagnostics World News | Funding for precision immunology pipeline, AI melanoma detection, multi-cancer early detection, and more.
Jun 29, 2022
-
Diagnostics World News | Last week Illumina launched a research test, codeveloped with Merck, that builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology. The test adds assessment of a new genomic signature to the distributed, market leading TruSight Oncology 500 assay.
Jun 27, 2022
-
Diagnostics World News | A Colorado State University team has designed metal ion-containing molecules that–alongside magnetic resonance imaging–could detect slight shifts in the human internal environment.
Jun 23, 2022
-
Diagnostics World News | A team of researchers from Guy's and St Thomas' NHS Foundation Trust and Oxford Nanopore have shared a novel protocol for the rapid metagenomic characterization of DNA and RNA viruses. The workflow identified pathogens in a matter of hours.
Jun 22, 2022
-
Diagnostics World News | The pandemic has thrown a spotlight on the Emergency Use Authorization (EUA) process of the U.S. Food and Drug Administration (FDA) whereby the agency can quickly give companies temporary permission to market unapproved medical products or unapproved uses of approved ones. The FDA’s EUA power has been in place a long time, and many such authorizations—including diagnostics specific to the Ebola and Zika viruses—remain open many years after declaration of the public health emergency that invoked it, according to B. Melina Cimler, Ph.D., CEO and founder of PandiaDx, a consultancy specializing in regulatory matters surrounding in vitro diagnostics.
Jun 21, 2022